Aurinia Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Aurinia Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Aurinia Pharmaceuticals: 13 sponsored US clinical trials, 2 recruiting.
Aurinia Pharmaceuticals sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 8 completed. 5 of these trials are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lupus Nephritis, with 1 trials.
Top-decile sponsor footprint
Aurinia Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
8 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (72.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
13 total, page 1 of 1
Study of Aritinercept in Patients With Generalized Myasthenia Gravis
NCT07596901
PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
NCT07611214
Long-Term Voclosporin Treatment in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05962788
Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis
NCT05288855
A Prospective Observational Registry of Patients Treated With LUPKYNIS® (Voclosporin) in the US
NCT05337124
Drug-Drug Interaction Study to Investigate Effects of Voclosporin on Pharmacokinetics of Simvastatin
NCT05306379
Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome
NCT04147650
Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin
NCT03597464
Ocular Tolerability of Voclosporin Ophthalmic Solution Versus Restasis® in Subjects With Dry Eye Disease
NCT03597139
Dose-Exploration Evaluating the Efficacy and Safety of Voclosporin in Subjects With Focal Segmental Glomerulosclerosis
NCT03598036
Aurinia Renal Response in Active Lupus With Voclosporin
NCT03021499
AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)
NCT02141672
Study of ISA247 (Voclosporin) in De Novo Renal Transplantation
NCT00270634
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 5 |
| Phase 3 | 4 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Aurinia Pharmaceuticals pipeline
2 recruiting of 13 indexed (15% open); 8 completed (62%).
Phase mix: 5 late (III/IV) vs 7 early (I/II) (balanced across stages).
Top condition: Lupus Nephritis (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Aurinia Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Aurinia Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Arrowhead Regional Medical Center · 15% recruiting · 13 trials
- Bronx VA Medical Center · 15% recruiting · 13 trials
- Candel Therapeutics · 15% recruiting · 13 trials
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk company · 15% recruiting · 13 trials
Related
What to do with this Aurinia Pharmaceuticals page
13 registered trials is a research-attention snapshot, not an endorsement of Aurinia Pharmaceuticals or any single study.
- 2 of Aurinia Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lupus Nephritis is the condition Aurinia Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lupus Nephritis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aurinia Pharmaceuticals pipeline card: 13 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.